Oncotarget

Research Papers:

Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panel

Chan Shen _, Funda Meric-Bernstam, Xiaoping Su, John Mendelsohn and Sharon Giordano

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:71686-71695. https://doi.org/10.18632/oncotarget.11994

Metrics: PDF 612 views  |   HTML 1304 views  |   ?  


Abstract

Chan Shen1,2, Funda Meric-Bernstam3, Xiaoping Su4, John Mendelsohn5,6, Sharon Giordano1

1Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

2Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

3Departments of Investigational Cancer Therapeutics and Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

4Departments of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

5Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

6Center for Health and Biosciences, Baker Institute, Rice University, Houston, TX, USA

Correspondence to:

Chan Shen, email: cshen@mdanderson.org

Keywords: genomic testing panel, cancer, costs, mutations, copy number alterations

Received: March 28, 2016    Accepted: August 24, 2016    Published: September 13, 2016

ABSTRACT

Interest in genomic testing for the selection of cancer therapy is growing. However, the cost of genomic testing has not been well studied. We sought to determine the price of identifying mutations and copy number alterations (CNAs) in theoretically actionable genes across multiple tumor types. We reviewed data from The Cancer Genome Atlas to determine the frequency of alterations in nine tumor types. We used price information from a commonly used commercial genomic testing platform (FoundationOne) to determine the price of detecting mutations and CNAs in different types of tumors. Although there are large variations in the prevalence by tumor type, when the detection of both mutations and CNAs was considered overall, most patients had at least one alteration in a potentially actionable gene (84% overall, range 51%- 98% among tumor types assessed). The corresponding average price of identifying at least one alteration per patient ranges from $5,897 to $11,572. Although the frequency of mutations and CNAs in actionable genes differs by tumor type, most patients have an actionable genomic alteration detectable by a commercially available panel. Determining CNAs as well as mutations improves actionability and reduces the price of detecting an alteration.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 11994